Development and evaluation of new nanoformulated thiolactone derivatives for enhanced disruption of pseudomonal biofilms.

Mohamed K Gaballah, Shaimaa A Khalid, Mohamed A Seleem, Amr K A Bass, Ibrahim M El-Sherbiny, Abdelrahman S Mayhoub

Abstract read

In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Rosa damascena-derived exosome-like nanovesicles inhibit Salmonella enterica via membrane disruption, oxidative stress, and virulence suppression.World journal of microbiology & biotechnology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamed K GaballahCenter of Certified Reference Materials (CRM), Zewail City of Science and Technology 6th of October City Giza 11566 Egypt amayhoub@zewailcity.edu.eg.

Shaimaa A KhalidNanomedicine Laboratories, Center for Materials Science, Zewail City of Science and Technology 6th October City 12578 Giza Egypt ielsherbiny@zewailcity.edu.eg.

Mohamed A SeleemCenter of Certified Reference Materials (CRM), Zewail City of Science and Technology 6th of October City Giza 11566 Egypt amayhoub@zewailcity.edu.eg.ORCID https://orcid.org/0000-0003-4379-5133

Amr K A BassDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Minufia University Shibin-Elkom 32632 Egypt.ORCID https://orcid.org/0000-0002-0588-0073

Ibrahim M El-SherbinyNanomedicine Laboratories, Center for Materials Science, Zewail City of Science and Technology 6th October City 12578 Giza Egypt ielsherbiny@zewailcity.edu.eg.ORCID https://orcid.org/0000-0002-8179-437X

Abdelrahman S MayhoubCenter of Certified Reference Materials (CRM), Zewail City of Science and Technology 6th of October City Giza 11566 Egypt amayhoub@zewailcity.edu.eg.ORCID https://orcid.org/0000-0002-3987-3680

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40556708

DOI10.1039/d5ra01831e

PMCPMC12186023

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.